COMMUNIQUÉS West-GlobeNewswire

Treace Medical Concepts Reports First Quarter 2026 Financial Results
08/05/2026
PONTE VEDRA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
ENvue Medical Adds to Intellectual Property Portfolio by Securing USPTO Notice of Allowance for Ultrasound-Enhanced Cannabinoid Drug Delivery Technology
08/05/2026
Patent Expands Company's Proprietary Surface Acoustic Wave Platform into Advanced Therapeutic Delivery Applications TYLER, Texas, May 08, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue," "ENvue [...]
Spectral Medical Announces First Quarter 2026 Financial Results and Provides Corporate Update
08/05/2026
PMA submission targeted for May 29, 2026 in alignment with FDA Vantive commits to additional funding support ahead of PMA acceptance milestone TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” [...]
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
08/05/2026
WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
08/05/2026
Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma ( [...]
Alamar Biosciences Reports First Quarter 2026 Financial Results
08/05/2026
FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for [...]
Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases
08/05/2026
Plenary session at AANS underscores REYOBIQ’s potential as a differentiated targeted radiotherapeutic platform for CNS cancers HOUSTON, Texas, May 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“ [...]
Global Ovarian Cancer Research Consortium Announces Next AI Accelerator Grant to Advance Data-Driven Discovery
08/05/2026
On World Ovarian Cancer Day, May 8, the Global Ovarian Cancer Research Consortium announces a second $1 million USD grant along with AWS compute support to power research to improve ovarian cancer survival rates TORONTO [...]
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
08/05/2026
- First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA modular application [...]
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
08/05/2026
Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in [...]
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
08/05/2026
OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment [...]
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
08/05/2026
Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no [...]
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
08/05/2026
ZUG, Switzerland, May 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs [...]
Profusa Receives Favorable Nasdaq Listing Determination
08/05/2026
BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring [...]
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
08/05/2026
Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-year Purified Cortrophin ® Gel net revenues of $75.1 million, an increase of 42.1% year-over-year Quarterly GAAP net income available to common [...]
ANGEL Expands U.S. Water Purification Lineup with New Whole House Water Filtration Systems
08/05/2026
LOS ANGELES, May 08, 2026 (GLOBE NEWSWIRE) -- ANGEL, a global water purification brand, today announced an expanded U.S. lineup of home water systems designed to make everyday water—used for drinking, cooking, and [...]
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
08/05/2026
Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or [...]
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
08/05/2026
SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for [...]
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
08/05/2026
Tokyo, Japan and Cambridge and London, UK, 8 May 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”) has issued [...]

Pages